Envelope surface glycoprotein gp120
|
env
|
HIV-1 JRFL Env (gp120) binds specifically to polystyrene-immobilized PF4 (CXCL4) and CCL5 (RANTES) as measured through ELISA |
PubMed
|
|
env
|
HIV-1 IIIB Env (gp120) upregulates production of TNF (TNF-a), IL-17A, CCL2 (MCP1), CCL5 (RANTES), IL6, IL10, CXCL8 (IL8), CXCL1 (GRO-a), and CCL1 (I309) in stimulated monocyte derived macrophages |
PubMed
|
|
env
|
Curcumin, a potent and safe anti-inflammatory compound, inhibits HIV-1 gp120-mediated upregulation of the proinflammatory cytokines TNF-alpha and IL-6, and the chemokines IL-8, RANTES, and IP-10 in primary human genital epithelial cells |
PubMed
|
|
env
|
The binding of HIV-1 gp120 to CCR5 and entry of macrophage-tropic HIV-1 isolates into cells is blocked by CCR5 antagonists or the chemokine RANTES, which interacts with CCR5 |
PubMed
|
|
env
|
HIV-1 gp120-induced neurodegeneration is significantly inhibited by overexpression of CCL5 in vivo |
PubMed
|
|
env
|
HIV-1 gp120-mediated upregulation of CCL5 expression requires the NF-kappaB pathway in astrocytes |
PubMed
|
|
env
|
Exposure of macrophages to purified CCR5- or CXCR4-tropic HIV-1 envelope glycoprotein gp120 induces secretion of high levels of macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, RANTES, and tumor necrosis factor alpha |
PubMed
|
|
env
|
NK cells exposed to CXCR4-tropic HIV-1 gp120 produce lower levels of CC chemokines RANTES, MIP-1alpha, and MIP-1beta compared with that produced from untreated NK cells |
PubMed
|
|
env
|
RANTES, stromal derived factor-1alpha (SDF-1alpha), macrophage-derived chemokine (MDC), and their combination attenuate HIV-1 gp120-induced food and water intake decrease in rats |
PubMed
|
|
env
|
HIV-1 gp120 induced cell death is inhibited by a CCR5-mediated neuroprotective pathway that involves protein kinase Akt/PKB as an essential component and can be triggered by the CCR5 agonists MIP-1beta and RANTES |
PubMed
|
|
env
|
CXCR4-tropic HIV-1 gp120 augments the expression of RANTES, IP-10, MCP-1, and LTN in peripheral blood mononuclear cells (PBMCs), while CCR5-tropic HIV-1 gp120 also induces an increase in both IP-10 and MCP-1 production |
PubMed
|
|
env
|
A synthetic peptide domain of the V3 region of HIV-1 gp120 activates the FPRL1 receptor in monocytes and neutrophils and causes reduced response to several chemokines that use multiple cell receptors, including SDF-1alpha and RANTES |
PubMed
|
|
env
|
Chemokines such as fractalkine, macrophage-derived chemokine (MDC), RANTES, and SDF-1alpha are able to block gp120-induced apoptosis of hippocampal neurons; both fractalkine and MDC activate ERK-1/2, while SDF-1alpha activates CREB |
PubMed
|
Envelope transmembrane glycoprotein gp41
|
env
|
A synthetic peptide corresponding to the immunosuppressive domain (amino acids 574-592) of HIV-1 gp41 inhibits activation of PBMCs and upregulates the expression of CCL5 in peptide-treated PBMCs |
PubMed
|
|
env
|
RANTES, MIP-1beta, and anti-CD4 antibodies inhibit CCR5-dependent cell-cell fusion mediated by HIV-1 gp120 and gp41 from macrophage-tropic isolates |
PubMed
|
|
env
|
HIV-1 gp41 stimulates microglial cell production of cytokines (TNF-alpha, IL-1beta, and IL-6) and chemokines (RANTES and MIP-1alpha) |
PubMed
|
Nef
|
nef
|
HIV-1 Nef specifically incorporates CSF2, PPBP (NAP2), CCL5, TNF, FAS, CXCL1, IL12B, MIF and OSM into plasma extracellular vesicles from HIV-1 infected patient samples |
PubMed
|
|
nef
|
Knockdown of C/EBPalpha, C/EBPgamma, and AP-1 by siRNA shows significant reduction of CCL5 levels, suggesting that C/EBPalpha, C/EBPgamma, and AP-1 proteins are involved in Nef-mediated upregulation of CCL5 |
PubMed
|
|
nef
|
Knockdown of p38 MAPK alpha or delta by siRNA shows significant reduction of CCL5 levels, suggesting that p38 MAPK alpha and delta proteins are involved in Nef-mediated upregulation of CCL5 |
PubMed
|
|
nef
|
Knockdown of AKT2 and AKT3 by siRNA shows significant reduction of CCL5 levels, suggesting that AKT2 and AKT3 proteins are involved in Nef-mediated upregulation of CCL5 |
PubMed
|
|
nef
|
Knockdown of the p50 and p65 subunits of NF-kappaB shows significant reduction of CCL5 levels, suggesting that NF-kappaB is involved in Nef-mediated upregulation of CCL5 |
PubMed
|
|
nef
|
HIV-1 Nef induces a time-dependent CCL5 upregulation in astrocytes |
PubMed
|
|
nef
|
HIV-1 Nef-pulsed iDCs downregulate MIP-1beta and RANTES expression in NK cells |
PubMed
|
|
nef
|
HIV-1 Nef upregulates the production of RANTES/CCL5 in microglial cells |
PubMed
|
Pr55(Gag)
|
gag
|
MVA-gag induces a significant release of cytokines such as IL-2R, IL-6, IL-8, TNF-alpha, IFN-gamma, MCP-1, MIP-1alpha, MIP-1beta, and RANTES by the infected monocyte-derived dendritic cells in comparison with uninfected cells |
PubMed
|
Tat
|
tat
|
HIV-1 Tat treatment alone or combination with methadone significantly upregulate RANTES production in mixed-glial cultures |
PubMed
|
|
tat
|
HIV-1 and the viral protein Tat modulate the expression of chemokine (C-C motif) ligand 5 (CCL5; RANTES) in immature dendritic cells and monocyte-derived macrophages |
PubMed
|
|
tat
|
HIV-1 Tat-mediated upregulation of CCL5 involves JAK2/3, AKT2/3, p38delta, NF-kappaB (p65/p50), C/EBP alpha/gamma, and AP-1 proteins |
PubMed
|
|
tat
|
Microarray analysis indicates HIV-1 Tat-induced upregulation of chemokine (C-C motif) ligand 5 (CCL5; RANTES) in primary human brain microvascular endothelial cells |
PubMed
|
|
tat
|
PACAP27-induced release of CCL5 inhibits HIV-1 Tat-mediated toxicity in human astrocytes |
PubMed
|
|
tat
|
Astrocyte cultures treated with morphine and Tat show exaggerated increases in chemokine release, including monocyte chemoattractant protein-1 (MCP-1), RANTES, and IL-6 |
PubMed
|
|
tat
|
HIV-1 Tat upregulates RANTES expression in monocyte-derived dendritic cells (MDDC), thereby driving Th1-type immune responses |
PubMed
|
|
tat
|
RANTES inhibits HIV-1 Tat-induced apoptosis, a protective effect mediated by the induction of MCP-1 |
PubMed
|
|
tat
|
HIV-1 Tat cooperates with RANTES in inducing monocyte migration |
PubMed
|
|
tat
|
RANTES is upregulated by HIV-1 Tat treatment in human epithelial cells |
PubMed
|
|
tat
|
HIV-1 Tat upregulates RANTES expression in human microglial cells, an effect that could contribute to the neuropathogenesis if HIV-1 |
PubMed
|
Vpr
|
vpr
|
HIV-1 Vpr upregulates the gene expression of CCL5 (RANTES) in human monocyte-derived dendritic cells |
PubMed
|
|
vpr
|
HIV-1 Vpr-induced upregulation of CCL5 requires p50 and p65 subunits of NF-kappaB, p38delta MAPK, Akt-2 and Akt-3, and AP-1 transcription factor in HIV-1 Vpr transfected astrocytes |
PubMed
|
|
vpr
|
HIV-1 Vpr upregulates expression of CCL5 and causes CCL5 co-localization with GFAP in the cytoplasm of astrocytes |
PubMed
|
|
vpr
|
HIV-1 Vpr regulates expression of RANTES, including upregulation in microglial cells and downregulation in primary lymphocytes and macrophages |
PubMed
|